Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine
Reference69 articles.
1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
2. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016
3. Role of epidermal growth factor receptor in lung cancer and targeted therapies;Liu;Am J Cancer Res,2017
4. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer;Malik;Oncology,2016
5. Randomized phase II trial of gefitinib with and without pemetrexed as first-Line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations;Cheng;J Clin Oncol,2016
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on KRAS Mutation;Current Issues in Molecular Biology;2024-07-16
2. Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update;Frontiers in Pharmacology;2023-01-09
3. ANGPTL4 Regulates Lung Adenocarcinoma Pyroptosis and Apoptosis via NLRP3\ASC\Caspase 8 Signaling Pathway to Promote Resistance to Gefitinib;Journal of Oncology;2022-11-25
4. Targeted Cancer Therapy: Tyrosine Kinase Inhibitors;Arşiv Kaynak Tarama Dergisi;2022-06-30
5. Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy;Frontiers in Chemistry;2021-11-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3